Body Weight Does Not Predict for Anti-Xa Levels after Fixed Dose Prophylaxis with Enoxaparin After Orthopedic Surgery

This publication has 16 references indexed in Scilit:

• Monitoring the Anticoagulant Effects of a Low Molecular Weight Heparin Preparation:Correlation of Assays in Orthopedic Surgery Patients Receiving Ardeparin Sodium for Prophylaxis of Deep Venous Thrombosis
  American Journal of Clinical Pathology, 1995
• Efficacy and Safety of Enoxaparin to Prevent Deep Venous Thrombosis after Hip Replacement Surgery
  Annals of Internal Medicine, 1994
• Comparison of warfarin and external pneumatic compression in prevention of venous thrombosis after total hip replacement
  JAMA, 1992
• LMW heparin (anti-Xa) assays for clinical monitoring and pharmacokinetic studies on the automated coagulation laboratory (ACL)
  Thrombosis Research, 1992
• Correlation between anti-Xa and occurrence of thrombosis and haemorrhage in post-surgical patients treated with either logiparin® (LMWH) or unfractionated heparin
  Thrombosis Research, 1992
• Prevention of deep vein thrombosis after hip replacement: randomised comparison between unfractionated heparin and low molecular weight heparin.
  BMJ, 1991
• Prevention of thromboembolism in 190 hip arthroplasties: Comparison of LMW heparin andplacebo
  Acta Orthopaedica, 1991
• A randomized trial of less intense postoperative warfarin or aspirin therapy in the prevention of venous thromboembolism after surgery for fractured hip
  Archives of internal medicine (1960), 1989
• Low molecular weight heparin compared with unfractionated heparin in prevention of postoperative thrombosis
  British Journal of Surgery, 1988
• A Randomized Controlled Trial of a Low-Molecular-Weight Heparin (Enoxaparin) to Prevent Deep-Vein Thrombosis in Patients Undergoing Elective Hip Surgery
  New England Journal of Medicine, 1986